

## Biomarkers of presbycusis and tinnitus in a Portuguese older population

Haúla Haider\*, Marisa Flook<sup>1</sup>, Diogo Ribeiro\*, Marília Antunes<sup>2</sup>, Agnieszka J Szczepek<sup>3</sup>, Derek J Hoare<sup>4</sup>, João Paço\* e Helena Caria<sup>1,5</sup>

\*ENT Department, Hospital Cuf Infante Santo - NOVA Medical School, Lisbon, Portugal;

<sup>1</sup>BioISI/FCUL, Lisbon, Portugal; <sup>2</sup> Centro de Estatística e Aplicações, FCUL, Lisbon, Portugal;

<sup>3</sup> Charite University Hospital, Berlin, Germany; <sup>4</sup> NIHR Nottingham Biomedical Research Centre, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, UK; <sup>5</sup>DCBM-ESS/IPS, Setúbal, Portugal

Haula.f.Haider@jmelloaude.pt

[hfhaider@gmail.com](mailto:hfhaider@gmail.com)

**Introduction:** Presbycusis or age-related hearing loss (ARHL) is a ubiquitous health problem. It is estimated that it will affect up to 1.5 billion people by 2025. In addition, tinnitus occurs in a large majority of cases with presbycusis. Glutamate metabotropic receptor 7 (*GRM7*) and N-acetyltransferase 2 (*NAT2*) are some of the genetic markers for presbycusis.

**Objectives:** To explore patterns of hearing loss and the role of *GRM7* and *NAT2* as possible markers of presbycusis and tinnitus in a Portuguese population sample.

**Materials and Methods:** Tonal and speech audiometry, tinnitus assessment, clinical interview, and DNA samples were obtained from patients aged from 55 to 75 with or without tinnitus. *GRM7* analysis was performed by qPCR. Genotyping of single nucleotide polymorphisms (SNPs) in *NAT2* was performed by PCR amplification followed by Sanger sequencing or by qPCR.

**Results:** We screened samples from 78 individuals (33 men and 45 women). T allele at *GRM7* gene was the most observed (60.3% T/T and 33.3% A/T). Individuals with a T/T genotype have a higher risk for ARHL and 33% lower risk for tinnitus, compared to individuals with A/A and A/T genotype, respectively. Being a slow acetylator (53%) was the most common *NAT2* phenotype, more common in men (55.8%). Intermediate acetylator was the second most common phenotype (35.9%) also more frequent in men (82.6%). Noise exposed individuals and individuals with 'high frequency' hearing loss seem to have a higher risk for tinnitus. Our data suggests that allele AT of *GRM7* can have a statistically significant influence towards the severity of tinnitus.

**Conclusion:** For each increasing year of age the chance of HL increases by 9%. The risk for ARHL was not significantly associated with *GRM7* neither *NAT2*. However we cannot conclude from our data whether the presence of T allele at *GRM7* increases the odds for ARHL or whether the A allele has a protective effect. Genotype A/T at *GRM7* could potentially be considered biomarkers of tinnitus severity. This is the first study evaluating the effect of *GRM7* and *NAT2* gene in tinnitus.

**Key Words:** Presbycusis, *GRM7*, *NAT2*, tinnitus, markers, comorbidities.

Remaining authors contacts:

**Marisa Flook**

Deafness Research group, BTR Unit, BioISI, Faculty of Sciences, University of Lisbon (FCUL),  
Portugal

[marisaflook@gmail.com](mailto:marisaflook@gmail.com)

**Diogo Ribeiro**

ENT Department, Hospital Cuf Infante Santo - NOVA Medical School, Travessa do Castro, 3.  
1350-070 Lisbon, Portugal

[dribeiro@icloud.com](mailto:dribeiro@icloud.com)

**Marilia Antunes**

Centro de Estatística e Aplicações, Faculdade de Ciências, Universidade de Lisboa,  
1749-016 Lisboa, Portugal

[marilia.antunes@fc.ul.pt](mailto:marilia.antunes@fc.ul.pt)

**Agnieszka J Szczepek**

Department of Otorhinolaryngology

Charite University Hospital

Chariteplatz 1

10117 Berlin, Germany

[Agnes.Szczepek@charite.de](mailto:Agnes.Szczepek@charite.de)

**Derek J Hoare**

NIHR Nottingham Biomedical Research Centre, Division of Clinical Neuroscience, School of  
Medicine, University of Nottingham, UK, NG7 2RD

[derek.hoare@nottingham.ac.uk](mailto:derek.hoare@nottingham.ac.uk)

**João Paço**

ENT Department, Hospital Cuf Infante Santo - NOVA Medical School, Travessa do Castro, 3.  
1350-070 Lisbon, Portugal

joao.paco@jmellosaude.pt

**Helena Caria**

Deafness Research group, BTR Unit, BioISI, Faculty of Sciences, University of Lisbon (FCUL),  
Portugal; ESS/IPS- Biomedical Sciences Department, School of Health, Polytechnic Institute of  
Setubal, Portugal

helena.caria@ess.ips.pt/mhcaria@fc.ul.pt